Initial clinical characterization of novel proximal biomarkers for Nx-1607, a first-inclass oral Cbl-B inhibitor, in patients with advanced malignancies
dc.contributor.author | Whelan, S. | |
dc.contributor.author | Karim, C. | |
dc.contributor.author | Ye, J. | |
dc.contributor.author | Ingallinera, T. | |
dc.contributor.author | Cherala, G. | |
dc.contributor.author | Jameson, K. | |
dc.contributor.author | Williams, A. | |
dc.contributor.author | Sharp, A. | |
dc.contributor.author | Krebs, Matthew G | |
dc.contributor.author | Pacey, S. | |
dc.contributor.author | Blagden, S. | |
dc.contributor.author | Plummer, R. | |
dc.contributor.author | Hochhauser, D. | |
dc.contributor.author | Evans, J. | |
dc.contributor.author | De Bono, J. | |
dc.contributor.author | Powers, J. | |
dc.date.accessioned | 2023-05-17T09:50:55Z | |
dc.date.available | 2023-05-17T09:50:55Z | |
dc.date.issued | 2022 | en |
dc.identifier.citation | Whelan S, Karim C, Ye J, Ingallinera T, Cherala G, Jameson K, et al. Initial Clinical Characterization of Novel Proximal Biomarkers for Nx-1607, a First-Inclass Oral Cbl-B Inhibitor, in Patients with Advanced Malignancies. Journal for immunotherapy of cancer. 2022 Nov;10:A809-A. PubMed PMID: WOS:000919423400733. | en |
dc.identifier.doi | 10.1136/jitc-2022-SITC2022.0777 | en |
dc.identifier.uri | http://hdl.handle.net/10541/626279 | |
dc.language.iso | en | en |
dc.relation.url | https://dx.doi.org/10.1136/jitc-2022-SITC2022.0777 | en |
dc.title | Initial clinical characterization of novel proximal biomarkers for Nx-1607, a first-inclass oral Cbl-B inhibitor, in patients with advanced malignancies | en |
dc.type | Meetings and Proceedings | en |
dc.contributor.department | Nurix Therapeutics, Inc., San Francisco, CA, | en |
dc.identifier.journal | Journal for Immunotherapy of Cancer | en |
dc.description.note | en] |